Business Opportunities in China: The Impact of the WTO - 2nd Edition

Countries covered: China Key points covered in this report: The development of the Chinese pharmaceutical industry and its current status Changes in the industry on China's accession to the WTO The competitiveness of the Chinese pharmaceutical industry in the international market The R&D and business opportunities for pharmaceutical firms considering alliances in China Significant points for consideration for companies looking to capture business opportunities in China.

Additional Information

Key points covered in this report:

• The development of the Chinese pharmaceutical industry and its current status
• Changes in the industry on China's accession to the WTO
• The competitiveness of the Chinese pharmaceutical industry in the international market
• The R&D and business opportunities for pharmaceutical firms considering alliances in China
• Significant points for consideration for companies looking to capture business opportunities in China.

This report discusses the state of the Chinese pharmaceutical industry and the opportunities available to companies doing business in China, and is aimed at individuals in business development and technology transfer looking to expand into China. China is one of the largest pharmaceuticals-producing countries in the world, and as it joins the World Trade Organization (WTO), it will need to integrate more completely into the global economy. This international competition will place an intense pressure on the Chinese pharmaceutical industry, and further open the door to a lucrative market for non-Chinese companies, especially for pharmaceutical producers and manufacturers.

This second edition, updated with new figures and tables based on Chinese official statistics, provides an overview of the development of the Chinese pharmaceutical industry and its current status, and a discussion of the competitiveness of the Chinese pharmaceutical industry in the international market. The report also provides an analysis of the business opportunities for pharmaceutical firms considering alliances in China, based on this research and the commitments made by Chinese authorities at the time of accession to the WTO, and concludes by highlighting the significant points for consideration for companies looking to capture such business opportunities in China.

The appendices include two case studies that explore examples of a 'Sino-foreign equity joint venture' and a 'Wholly foreign-owned company' in China, references, a glossary of terms, the source data used in the figures, and a resources section.

Who should buy the report
This report is suitable to individuals responsible for and interested in:

• Board and executive management
• Business development
• Licensing/partnering
• Deal making
• Business strategy

Companies analyzed/mentioned
Case studies:

• Sino-Swed Pharmaceutical Corp. LTD (SSPC)
• Pfizer (China) Pharmaceuticals Limited

China has established a pharmaceutical industry structure, and has become one of the largest pharmaceuticals-producing countries in the world. As China joins the World Trade Organization (WTO), it will need to integrate more completely into the global economy. This international competition will place an intense pressure on the Chinese pharmaceutical industry, and further open the door to a lucrative market for non-Chinese companies, especially for pharmaceutical producers and manufacturers. Accession to the WTO will bind China by fundamental WTO principles, such as improved transparency and the strengthening of commercial legal procedures. China's WTO commitments include the tightening of rules on intellectual property, tariff concessions, and market access of non-Chinese service suppliers engaging in the distribution of pharmaceuticals. All such moves will create additional business opportunities for non-Chinese pharmaceutical companies in China, and in turn, place an intense pressure on the Chinese pharmaceutical industry.

This report will discuss the state of the Chinese pharmaceutical industry and the opportunities available to companies doing business in China, based on Chinese official statistics. Section 2 provides an overview of the development of the Chinese pharmaceutical industry, and its current status. Section 3 discusses the competitiveness of the Chinese pharmaceutical industry in the international market. Section 4 provides an analysis of the business opportunities for pharmaceutical firms considering alliances in China, based on this research and the commitments made by Chinese authorities at the time of accession to the WTO. The report concludes (section 5) by highlighting the significant points for consideration for companies looking to capture such business opportunities in China. The appendices (section 6) include two case studies that explore examples of a 'Sino-foreign equity joint venture' and a 'Wholly foreign-owned company' in China, references, a glossary of terms, the source data used in the figures, and a resources section.

More China International Trade Reports

Latest Chinese Guide to Industrial Access for Foreign Companies and Investors by Access China Management Consulting Ltd.
Latest Chinese Guide to Industrial Access for Foreign Companies and Investors published by Access China Management Consulting Ltd provides the detailed guidance of latest Chinese ...

China - ISA Country Report by ISA (International Strategic Analysis)
This report contains detailed forecasts and analysis for China, including trade and investment analysis, economic forecasts, political risk assessments and demographic trend analysis. Each ...

China: Country Economic Forecast: 24 Apr 2012 by Oxford Economics
GDP growth in China slowed to 8.1% in 2012Q1 from 8.9% in 2011Q4. Exports and investment were weak, cutting growth more sharply than expected, but ...

Guidebook Series for Investing in China (Second Edition) by Access China Management Consulting Ltd.
Access China Management Consulting Ltd has worked hard to the second edition of the Guidebook Series for Investing in China in order to deal with ...

Collection of Chinese Laws and Administrative Regulations for Application and Approval of Foreign Investment Projects and Business Scope The Invest in China Guidebook Series (4) (Second Edition) by Access China Management Consulting Ltd.
Access China Management Consulting Ltd has worked hard to the second edition of the Guidebook Series for Investing in China in order to deal with ...

See all reports like this >>

More China Reports

D&B Country RiskLine Report: China by Dun & Bradstreet Inc.
This D&B Country RiskLine Report will help you analyze the risks, opportunities and likely payment delays when doing business in this country. It includes ...

Country Report China February 2011 by Economist Intelligence Unit
Country Reports analyse political and economic trends in featured countries. They show you exactly how national, regional and global events will affect your business in ...

Country Report China January 2011 by Economist Intelligence Unit
Country Reports analyse political and economic trends in featured countries. They show you exactly how national, regional and global events will affect your business in ...

D&B Country Report: China by Dun & Bradstreet Inc.
D&B Country Report. Comprehensive information for evaluating risks and opportunities when trading or investing in this country. Providing critical information and analysis on ...

Wine - BRIC (Brazil, Russia, India, China) Industry Guide by MarketLine
Datamonitor's Wine - BRIC (Brazil, Russia, India, China) Industry Guide is an essential resource for top-level data and analysis covering the BRIC (Brazil, Russia, India, ...

See all reports like this >>